PMID- 10489873
OWN - NLM
STAT- MEDLINE
DCOM- 19991025
LR  - 20190915
IS  - 0253-6269 (Print)
IS  - 0253-6269 (Linking)
VI  - 22
IP  - 4
DP  - 1999 Aug
TI  - Effect of DA-6034, a derivative of flavonoid, on experimental animal models of 
      inflammatory bowel disease.
PG  - 354-60
AB  - Inflammatory bowel disease (IBD) is a multifactorial disorder with unknown 
      etiology and pathogenesis. DA-6034, 7-carboxymethyloxy-3', 4', 5-trimethoxy 
      flavone, is a synthetic flavonoid known to possess anti-inflammatory activity. 
      This study was performed to evaluate the oral therapeutic effect of DA-6034 in 
      three experimental animal models of IBD: two chemical-induced IBD models of rats 
      and the human leukocyte antigen (HLA)-B27 transgenic rat model known to develop 
      spontaneous colitis without the use of exogenous agents. Acute chemical colitis 
      was induced by intracolonic instillation of 1.2 ml of 4% acetic acid solution. 
      Prednisolone (1 mg/kg), sulfasalazine (100 mg/kg) and DA-6034 (0.3 to 
      approximately 3 mg/kg) were orally administered twice daily for 6 days in these 
      rats. In addition, chronic chemical colitis was induced by intracolonic 
      administration of trinitrobenzene sulfonic acid (TNBS) 30 mg in 50% ethanol and 
      agents were orally administered for 6 or 20 days. In chemical-induced IBD models, 
      all of these agents reduced the severity of colitis and specially, DA-6034 (3 
      mg/kg) showed more potent effect than other drugs in macroscopic lesion score. In 
      HLA-B27 transgenic rats, DA-6034 (3 mg/kg) and prednisolone (0.5 mg/kg) were 
      treated orally twice daily for 6 weeks. The HLA-B27 transgenic rats showed only 
      mild colitis, compared with the chemical-induced colitis models. DA-6034 
      ameliorated the loose stool and decreased microscopic damage, which is the 
      important indicator of this model. In conclusion, oral therapy of DA-6034 
      attenuated the macroscopic and histologic damages of the colon in all three 
      experimental models of IBD, which suggest that DA-6034 could be a promising drug 
      in the treatment of IBD.
FAU - Kim, Y S
AU  - Kim YS
AD  - Department of Internal Medicine, Seoul National University, College of Medicine, 
      Korea.
FAU - Son, M
AU  - Son M
FAU - Ko, J I
AU  - Ko JI
FAU - Cho, H
AU  - Cho H
FAU - Yoo, M
AU  - Yoo M
FAU - Kim, W B
AU  - Kim WB
FAU - Song, I S
AU  - Song IS
FAU - Kim, C Y
AU  - Kim CY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Korea (South)
TA  - Arch Pharm Res
JT  - Archives of pharmacal research
JID - 8000036
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Flavonoids)
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (HLA-B27 Antigen)
RN  - 0 (beta 2-Microglobulin)
RN  - 3XC8GUZ6CB (Sulfasalazine)
RN  - 8T3HQG2ZC4 (Trinitrobenzenesulfonic Acid)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - Q40Q9N063P (Acetic Acid)
RN  - U96J5LG435 (recoflavone)
SB  - IM
MH  - Acetic Acid
MH  - Animals
MH  - Animals, Genetically Modified
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Colitis/chemically induced/drug therapy
MH  - Flavonoids/*pharmacology
MH  - Gastrointestinal Agents/therapeutic use
MH  - HLA-B27 Antigen/genetics/immunology
MH  - Humans
MH  - Inflammatory Bowel Diseases/chemically induced/*drug therapy/pathology
MH  - Organ Size/drug effects
MH  - Prednisolone/therapeutic use
MH  - Rats
MH  - Sulfasalazine/therapeutic use
MH  - Trinitrobenzenesulfonic Acid
MH  - Weight Loss/drug effects
MH  - beta 2-Microglobulin/genetics/immunology
EDAT- 1999/09/18 00:00
MHDA- 1999/09/18 00:01
CRDT- 1999/09/18 00:00
PHST- 1999/09/18 00:00 [pubmed]
PHST- 1999/09/18 00:01 [medline]
PHST- 1999/09/18 00:00 [entrez]
AID - 10.1007/BF02979057 [doi]
PST - ppublish
SO  - Arch Pharm Res. 1999 Aug;22(4):354-60. doi: 10.1007/BF02979057.